KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Gilead Sciences (GILD) Research & Development (2016 - 2026)

Gilead Sciences filings provide 17 years of Research & Development readings, the most recent being $1.6 billion for Q4 2025.

  • On a quarterly basis, Research & Development fell 3.47% to $1.6 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $5.8 billion, a 1.81% decrease, with the full-year FY2025 number at $5.8 billion, down 1.83% from a year prior.
  • Research & Development hit $1.6 billion in Q4 2025 for Gilead Sciences, up from $1.3 billion in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $1.6 billion in Q4 2024 to a low of $1.1 billion in Q1 2021.
  • Median Research & Development over the past 5 years was $1.4 billion (2024), compared with a mean of $1.4 billion.
  • Biggest five-year swings in Research & Development: fell 15.94% in 2021 and later increased 27.68% in 2023.
  • Gilead Sciences' Research & Development stood at $1.4 billion in 2021, then increased by 13.99% to $1.5 billion in 2022, then decreased by 9.04% to $1.4 billion in 2023, then increased by 16.55% to $1.6 billion in 2024, then decreased by 3.47% to $1.6 billion in 2025.
  • The last three reported values for Research & Development were $1.6 billion (Q4 2025), $1.3 billion (Q3 2025), and $1.5 billion (Q2 2025) per Business Quant data.